China Doing Very Well in Covid-19 Fight: Qiming Venture Partners

The transcript discusses the efforts of Chinese companies in fighting COVID-19, highlighting advancements in diagnostics, drug development, and vaccines. It covers the challenges faced by CanSino Biologics in clinical trials and the impact of geopolitical tensions on healthcare innovation. The discussion also touches on private equity funding and investment trends in China, noting a decline in VC investments and the shift in company listings from the US to Hong Kong.

How do geopolitical tensions between the US and China affect collaboration in healthcare innovation?

What impact has the COVID-19 pandemic had on venture capital investment in tech and biotech in China?

What are the expectations for future IPOs within the Tsimane portfolio in the coming months?